How has Eton Pharmaceuticals performed over the past 5 years?
-127.1%
Last years earnings growth
Earnings and Revenue History
Quality Earnings: ETON is currently unprofitable.
Growing Profit Margin: ETON is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if ETON's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare ETON's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ETON is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (21.3%).
Return on Equity
High ROE: ETON has a negative Return on Equity (-156.74%), as it is currently unprofitable.
What is Eton Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate ETON's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate ETON's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ETON's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ETON's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ETON's dividend in 3 years as they are not forecast to pay a notable one for the US market.
What is the CEO of Eton Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?
2.5yrs
Average board tenure
CEO
SeanBrynjelsen(47yo)
2.5yrs
Tenure
US$493,022
Compensation
Mr. Sean E. Brynjelsen has been the Chief Executive Officer at Eton Pharmaceuticals, Inc. since June 23, 2017 and serves as President and Director since June 2017. Mr. Brynjelsen served as Executive Vice PÂ ...
CEO Compensation Analysis
Compensation vs Market: Sean's total compensation ($USD493.02K) is about average for companies of similar size in the US market ($USD508.62K).
Compensation vs Earnings: Sean's compensation has been consistent with company performance over the past year.
Board Age and Tenure
2.5yrs
Average Tenure
61yo
Average Age
Experienced Board: ETON's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
BuyUS$30,75013 Aug 19
Sean Brynjelsen
Entity
Individual
Role
Chief Executive Officer
President
Shares
5,000
Max Price
US$6.15
BuyUS$21,37012 Aug 19
Charles Casamento
Entity
Individual
Role
Member of the Board of Directors
Independent Director
Shares
3,500
Max Price
US$6.11
BuyUS$79,32622 May 19
Sean Brynjelsen
Entity
Individual
Role
Chief Executive Officer
President
Shares
10,000
Max Price
US$7.96
Ownership Breakdown
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 269.2%.
Management Team
Sean Brynjelsen (47yo)
President
Tenure: 2.5yrs
Compensation: US$493.02k
W. Troutman (64yo)
CFO, Treasurer & Secretary
Tenure: 2.4yrs
Compensation: US$296.55k
Bharathi Devarakonda
Senior Vice President of Regulatory Affairs & Product Development
Tenure: 0yrs
Scott Grossenbach
Vice President of Sales & Marketing
Tenure: 0yrs
Board Members
Paul Maier (71yo)
Independent Director
Tenure: 2.3yrs
Compensation: US$125.00k
Chuck Casamento (74yo)
Independent Director
Tenure: 2.5yrs
Compensation: US$125.00k
Norbert Riedel (61yo)
Chairman
Tenure: 1.3yrs
Compensation: US$125.00k
Mark Baum (46yo)
Director
Tenure: 2.7yrs
Compensation: US$125.00k
Sean Brynjelsen (47yo)
President
Tenure: 2.5yrs
Compensation: US$493.02k
Company Information
Eton Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products. It primarily focuses on liquid products, including injectable, oral liquid ...
Company Analysis and Financial Data Status
All financial data provided by Standard & Poor's Capital IQ.
Data
Last Updated (UTC time)
Company Analysis
2019/12/08 00:31
End of Day Share Price
2019/12/06 00:00
Earnings
2019/09/30
Annual Earnings
2018/12/31
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.